For the Inventor, By the Inventor

Enter assignee name

Calgary, Canada

Resverlogix Corporation

USPTO Granted Patents = 21

CIPO Patents = 5

EPO Patents = 13

Trademarks = 1

Forward Citations = 269

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Henrik C Hansen (17 out of 18 patents)

Norman C W Wong (5 out of 5 patents)

Fabrizio S Chiacchia (5 out of 5 patents)

4. David Robert McCaffrey (4 out of 5 patents)

5. Joseph E L Tucker (4 out of 4 patents)

6. Ewelina B Kulikowski (3 out of 3 patents)

7. Dean E Gilham (2 out of 2 patents)

8. Sylwia Wasiak (2 out of 2 patents)

9. Christopher R A Halliday (2 out of 2 patents)

10. Narmada R Shenoy (2 out of 6 patents)

11. Jan Johansson (1 out of 9 patents)

12. Gregory Steven Wagner (1 out of 18 patents)

13. George Yiannikouros (1 out of 16 patents)

14. Laura M Tsujikawa (1 out of 2 patents)

15. Sarah C Attwell (1 out of 1 patent)

21 patents: Sort by Forward Citations

1. 11407719 - Anti-inflammatory agents (2022-08-09),

2. 10882828 - Anti-inflammatory agents (2021-01-05),

3. 10772894 - Compositions and therapeutic methods for the treatment of complement-associated diseases (2020-09-15),

4. 10532054 - Compounds for the prevention and treatment of cardiovascular diseases (2020-01-14),

5. 10131640 - Anti-inflammatory agents (2018-11-20),

6. 10111885 - Compositions and therapeutic methods for the treatment of complement-associated diseases (2018-10-30),

7. 10016426 - Pharmaceutical compositions for substituted quinazolinones (2018-07-10),

8. 9757368 - Anti-inflammatory agents (2017-09-12),

9. 9610251 - Pharmaceutical compositions for substituted quinazolinones (2017-04-04),

10. 9238640 - Anti-inflammatory agents (2016-01-19),

11. 9199990 - Compounds for the prevention and treatment of cardiovascular diseases (2015-12-01),

12. 8952021 - Compounds for the prevention and treatment of cardiovascular disease (2015-02-10),

13. 8889698 - Compounds for the prevention and treatment of cardiovascular diseases (2014-11-18),

14. 8884046 - Compounds useful in the synthesis of benzamide compounds (2014-11-11),

15. 8410109 - Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices (2013-04-02),

Resverlogix Corporation (Resverlogix) is a biotechnology company focused on developing innovative therapies for patients with chronic diseases. With a strong emphasis on epigenetics, Resverlogix is dedicated to discovering and advancing novel small molecule therapeutics that target epigenetic pathways in order to address unmet medical needs. The company's lead product candidate, Apabetalone, is being investigated as a potential treatment for cardiovascular and other chronic diseases with significant unmet needs. Resverlogix's mission is to improve patients' quality of life and potentially extend their lifespan by developing breakthrough treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#51 in Calgary

#648 in Canada

#29,080 in the World

Calgary, Canada

Resverlogix Corporation

Forward Citations = 269

22 inventors:

Henrik C Hansen (17 out of 18 patents)

Norman C W Wong (5 out of 5 patents)

Fabrizio S Chiacchia (5 out of 5 patents)

4. David Robert McCaffrey (4 out of 5 patents)

5. Joseph E L Tucker (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…